Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients by Boyoung Park et al.
EPIDEMIOLOGY
Characteristics of BRCA1/2 mutations carriers including large
genomic rearrangements in high risk breast cancer patients
Boyoung Park1,10 • Ji Yeon Sohn2 • Kyong-Ah Yoon8,9 • Keun Seok Lee3 •
Eun Hae Cho7 • Myong Cheol Lim4,5 • Moon Jung Yang3 • Soo Jin Park3 •
Moo Hyun Lee3,11 • See youn Lee3 • Yoon Jung Chang1,10 • Dong Ock Lee4 •
Sun-Young Kong1,2,6 • Eun Sook Lee1,3,9
Received: 19 September 2016 / Accepted: 6 February 2017 / Published online: 15 February 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Purpose We investigated the prevalence of BRCA1/2
small mutations and large genomic rearrangements in high
risk breast cancer patients who attended a genetic coun-
seling clinic.
Methods In total 478 patients were assessed for BRCA1/2
mutations by direct sequencing, of whom, 306 were iden-
tified as non-carriers of BRCA1/2 mutation and assessed for
large rearrangement mutations by multiplex ligation-de-
pendent probe amplification. Family history and clinico-
pathological characteristics of patients were evaluated.
Results Sixty-three mutation carriers (13.2%) were iden-
tified with BRCA1 mutations (6.3%) and BRCA2 mutations
(6.9%), respectively. Mutation frequency was affected by
familial and personal factors. Breast cancer patients with
family history of breast and ovarian cancer showed the
highest prevalence of BRCA1/2 mutations (67%), and tri-
ple-negative breast cancer (TNBC) patients showed high
BRCA1 mutation prevalence (25%). The three probands of
BRCA1 deletion (1%) represented both familial risk and
personal or clinicopathological risk factors as two with
TNBC and one with bilateral ovarian cancer.
Discussion This is the largest study assessing large geno-
mic rearrangement prevalence in Korea and BRCA1 dele-
tion frequency was low as 1% in patients without BRCA1/2
small mutations. For clinical utility of large genomic
rearrangement testing needs further study.
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Introduction
Germline mutations in the BRCA1/2 genes are the most
important cause of hereditary breast cancer [1]. The aver-
age cumulative risk of breast cancer in female carriers
above 70 years is estimated to be 57–65 and 45–49% for
BRCA1 and BRCA2 mutation carriers, respectively [2, 3].
Risk of hereditary cancers is assessed by taking into
account familial and personal factors or clinicopathological
characteristics of cancers such as triple-negative breast
cancers (TNBC), which do not express the genes for
estrogen receptor (ER), progesterone receptor (PR), or
HER2 receptor [4]. With this information, women with a
high risk of developing hereditary cancers are recom-
mended to be tested for mutations in BRCA1/2 genes [5, 6].
Given that BRCA1/2 mutation test targets a test targets a
high-risk population and the further management plans are
largely dependent on the results of BRCA1/2 mutation
testing are important.
Direct Sanger sequencing, conformation-sensitive gel
electrophoresis, and denaturing high-performance liquid
chromatography have been used to identify BRCA1/2
mutations. However, these techniques cannot identify large
genomic rearrangements, which are often reported in
patients with negative results from conventional direct
sequencing [7, 8]. This may lead to an underestimation of
mutation prevalence and provide false-negative informa-
tion to patients and their families. Previous studies showed
varying results with the prevalence of large genomic
rearrangements ranging from 0 to 30% [9–14]. This wide
range might be caused by different genetic backgrounds
and the different inclusion criteria of various studies [11].
Thus, we investigated the prevalence of BRCA1/2 large
genomic rearrangements using multiplex ligation-depen-
dent probe amplification in high-risk breast cancer patients




All the patients who were referred to a genetic counseling
clinic and screened for BRCA1/2 mutation, at the National
Cancer Center between April 2008 and 2015, were initially
considered for this study. Among the total 523 patients
screened for BRCA1/2 mutations, we excluded 28 family
members of known BRCA1/2 mutation carriers and 17
patients with other types of cancers. There were 478 pro-
bands with breast cancer included in this study. The
referred criteria for breast cancer were: (1) breast cancer
patients with a family history of breast or ovarian cancer;
(2) breast cancer patients who were 40 years or younger
during diagnosis, who had bilateral breast cancer or breast
cancer with other primary malignancy, or male breast
cancer patients, in accordance with the standard of
National Medical Insurance Reimbursement in Korea. In
the genetic counseling process, all patients’ mutation
probabilities were estimated by CaGene5.0 software [15]
using pedigree information up to second-degree relatives
and considering estimates by BRCAPRO [16] and Myriad
[17]. Clinicopathological characteristics of cancer, such as
the stage and the hormone receptor and human epidermal
growth factor receptor 2 (HER2) status, were evaluated by
reviewing medical records.
The initial BRCA1/2 mutation test was performed by
PCR amplification and direct sequencing covering all
exons and flanking intronic sequences. A subset (73%) of
the 418 cases designated as non-carriers by direct
sequencing, agreed to participate in the study. Written
informed consent was obtained from 306 patients, and they
were screened for the presence of large genomic rear-
rangements using a multiplex ligation-dependent probe
amplification (MLPA) assay. This study protocol was
approved by the institutional review board of the National
Cancer Center (NCC2015-0177). The selection of patients
and the test process is presented in the Fig. 1.
Direct sequencing for mutation detection of BRCA1
and BRCA2, and nomenclature
Genomic DNA was extracted from peripheral blood using
the Chemagic DNA Blood 200 Kit (Chemagen, Baeswei-
ler, Germany). Amplified products were sequenced on an
ABI 3500xl analyzer (Applied Biosystems, Foster City,
CA, USA), using the Bigdye Terminator v3.1 Cycle
Sequencing Kit. Sequences were analyzed using
Sequencher v4.10.1 software. The clinical significance of
each sequence variation was determined according to the
Breast Cancer Information Core database (BIC: http://
research.nhgri.nih.gov/bic/) and the recommendations of
the American College of Medical Genetics [18]. All the
mutations are described according to HUGO-approved
systematic nomenclature (http://www.hgvs.org/mutnomen/).
GenBank accession sequences NM_007294.3 and NM_
000059.3 were used as reference sequences for BRCA1 and
BRCA2, respectively. Traditional mutation nomenclatures of
the BIC were used for description.
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Multiplex ligation-dependent probe amplification
MLPA was performed to detect large genomic rearrange-
ments using the SALSA P002-D1 BRCA1 Kit (MRC
Holland, Amsterdam, Holland) for BRCA1 and P045-B3
BRCA2 Kit (MRC Holland, Amsterdam, Holland) for
BRCA2. PCR products were analyzed using an ABI 3500xl
analyzer with GeneMarker v2.4.0 demonstration program
(Softgenetics, State College, PA, USA). Peak heights were
normalized, and a deletion or duplication was identified
when the normalized peak ratio value was below 0.75 or
above 1.30, respectively.
Risk factors and statistical analysis
The subjects were classified according to familial and
personal factors. Familial factors taken into account
included family history of breast cancer, number of family
members with breast cancer, closest degree of family
members with breast cancer, and family history of ovarian
cancer. Forty-two of the 306 patients had a family history
of ovarian cancer. Personal factors taken into account
included early onset of breast cancer which is defined as
the development of breast cancer before the age of 40,
bilateral breast cancer irrespective of age at onset, both
breast and ovarian cancer irrespective of age at onset,
multiple organ cancers defined as breast cancer patients
with other primary organ cancer except ovarian cancer, and
male cancer. The clinicopathological factors considered
were age at diagnosis of breast cancer, stage, and the
hormone receptor (including estrogen and PR) and HER2
status.
The frequencies of mutations were presented according
to familial and personal factors and clinicopathological
characteristics. All analyses were conducted using SAS 9.2
software (SAS Institute, Cary, NC).
Results
Mutational status according to subjects’
characteristics
Pathogenic mutations in BRCA1/2 genes, including large
genomic rearrangements, were detected in 63 of 478
(13.2%) patients. In total, 30 BRCA1 mutation carriers
(6.3%) and 33 BRCA2 mutation carriers (6.9%) were
identified. Table 1 shows the frequency of BRCA1/2
Subjects
(N=523)
Targeted sequencing in 






















BRCA1 and BRCA2 MLPA
(N=306)
Final subjects considered to be no
pathogenic mutation/deletion
(N=415)
Fig. 1 The study
flowchart outlining the number
of subjects and the genetic
testing approach used in the
study. A total of 478 breast
cancer patients were included
and multiple ligation-dependent
probe amplification (MLPA)
analysis was performed for 306
patients who did not have small
mutations in the BRCA1 and
BRCA2 genes and agreed for
this study
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Table 1 The frequencies of BRCA1 and BRCA2 mutationsa in high-risk breast cancer patients according to familial and personal risk factors
(N = 478)
Risk category Total BRCA1 mutation BRCA2 mutation BRCA1/2 mutation
N (%d) N (%e) N (%e) N (%e)
Family history
Breast cancer family only (without ovarian cancer)§ 303 (63.4) 14 (4.6) 29 (9.6) 43 (14.2)
1 breast cancer family 253 (52.9) 11 (4.4) 17 (6.7) 28 (11.1)
2 Bbreast cancer families*,§ 50 (10.5) 3 (6.0) 12 (24.0) 15 (30.0)
Breast cancer families in 1st degree relativesb 217 (45.4) 13 (6.0) 20 (9.2) 33 (15.2)
Breast cancer families in second/third degree relativesb,§ 86 (18.0) 1 (1.2) 9 (10.5) 10 (11.6)
Ovarian cancer familyb
Without breast cancer§ 29 (6.1) 6 (20.7) 0 (0.0) 6 (20.7)
With breast cancer* 13 (2.7) 4 (30.8) 2 (15.4) 6 (46.2)
Any of breast/ovarian cancer familiesc,* 345 (72.2) 24 (7.0) 31 (9.0) 55 (15.9)
No family history* 133 (27.8) 6 (4.5) 2 (1.5) 8 (6.0)
Personal history
Early-onset breast cancer (age\ 40) 199 (41.6) 12 (6.0) 11 (5.5) 23 (11.6)
Bilateral breast cancer 47 (9.8) 2 (4.3) 5 (10.6) 7 (14.9)
Multiple organ cancersf 27 (5.6) 0 (0.0) 2 (7.4) 2 (7.4)
Both breast and ovarian cancer* 6 (1.3) 3 (50.0) 1 (16.7) 4 (66.7)
Male breast cancer 4 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Clinicopathological factor
Age at diagnosis
\40 186 (38.9) 12 (6.5) 11 (6.8) 23 (14.3)
40–49 172 (36.0) 10 (5.8) 15 (8.7) 25 (14.5)
50–59 89 (18.6) 7 (7.9) 6 (6.7) 13 (14.6)
60–79 31 (6.5) 1 (3.3) 1 (3.3) 2 (6.5)
Stage*
0 55 (11.5) 0 (0.0) 0 (0.0) 0 (0.0)
I 173 (36.2) 12 (6.9) 12 (6.9) 24 (13.9)
II 159 (33.3) 12 (7.6) 18 (11.3) 30 (18.9)
III? 88 (18.4) 5 (7.4) 2 (2.9) 7 (10.3)
Unknown 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Hormone receptor status*,§
ER? & PR? 307 (64.2) 5 (1.6) 25 (8.1) 20 (9.8)
ER? & PR- 44 (9.2) 1 (2.3) 4 (9.1) 5 (11.4)
ER- & PR? 7 (1.5) 1 (14.3) 0 (0.0) 1 (14.3)
ER- & PR- 115 (24.1) 23 (20.0) 4 (3.5) 27 (23.5)
Unknown 5 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Subtype according to hormone receptor and HER2 status*,§
HR? & HER2- 252 (52.7) 6 (2.4) 19 (7.5) 25 (9.9)
HR- & HER2? 28 (5.9) 1 (3.6) 0 (0.0) 1 (3.6)
HR? & HER2? 37 (7.7) 0 (0.0) 2 (5.4) 2 (5.4)
Triple-negative 76 (15.9) 19 (25.0) 3 (4.0) 22 (29.0)
Unclassifiable 85 (17.8) 4 (4.7) 9 (10.6) 13 (15.3)
Total 478 (100.0) 30 (6.3) 33 (6.9) 63 (13.2)
HR hormone receptor, HER2 human epidermal growth factor receptor 2
* P value\0.05 for BRCA1/2 mutation prevalence between those included in each category and those not
§ P value\0.05 between BRCA1 and BRCA2 ratio in carriers
a Including three patients with large genomic rearrangements in BRCA1 gene
b Among 42 patients who had family history of ovarian cancer, 40 had one family member with ovarian cancer history and 2 had two family
members with ovarian cancer history
c Closest degree of relatives with breast cancer
d Percent among all subjects (column percent)
e Percent among subjects with each risk category (row percent)
f Multiple organ cancer was defined as breast cancer patients with other primary organ cancer except ovarian cancer
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mutations according to familial and personal factors, and
clinicopathological characteristics. BRCA1/2 mutation
prevalence in familial breast cancer cases was 15.9%,
which was significantly higher in non-familial breast can-
cer cases (6.0%, P = 0.004). When personal factors were
considered, BRCA1/2 mutations were observed in 11.6% of
early-onset breast cancer patients, 14.9% of bilateral breast
cancer patients, and 66.7% of patients who were diagnosed
with both breast and ovarian cancer. The prevalence of
BRCA1/2 mutations also differed significantly according to
hormone receptor and HER2 status (P = 0.003
and\0.001, respectively). The prevalence of BRCA1/2
mutation according to the combinations of familial and
personal factors with denominators and numerators is
described in Appendix Table 4.
Patients with large genomic rearrangements
Three BRCA1 deletion carriers were identified by MLPA
from 306 patients BRCA1/2 mutation negative by standard
sequencing. These deletion mutations account for 10% of
all BRCA1 mutation carriers (Fig. 1). The characteristics of
each patient are summarized in Table 2 and detailed
explanation is as following. Patient A, diagnosed with
ductal carcinoma in situ with TNBC at the age of 51,
carried exons 5–8 deletion (Fig. 2a). She had a second- and
a third-degree relative with breast cancer. Estimated
mutation probabilities for BRCA1/2 before mutation test
were 0.8% by BRCAPRO and 5.3% by Myriad. Following
genetic counseling about the BRCA1 deletion, genetic
testing was performed on her daughter and three sisters
without breast cancer and her daughter was found to have
the same deletion.
Patient B, diagnosed with stage III TNBC at the age of
35, carried exons 22–24 deletion (Fig. 2b). The patient had
a first-degree relative with ovarian cancer and a sec-
ond-degree relative with breast cancer. Estimated
mutation probabilities for BRCA1/2 mutation test were
57.2% by BRCAPRO and 39.2% by Myriad. Genetic
testing was performed on her four sisters without breast
cancer and of them, two sisters were found to have the
deletion.
Patient C, was diagnosed with bilateral stage I breast
cancer for the first time at age 33 and for the second time at
age 46. She was not a TNBC case, and carried a BRCA1
gene lacking exons 1–14 (Fig. 2c). The estimated mutation
probabilities for BRCA1/2 mutation test were 51.2% by
BRCAPRO and 15.8% by Myriad. After enrollment in this
study, she was newly diagnosed with ovarian cancer.
Genetic testing was performed on her two sisters and one
of her sisters, diagnosed before with bilateral breast cancer,
carried a BRCA1 gene with the same large genomic
rearrangements.
Pathogenic variants of BRCA1/2 genes found in this
study
The pathogenic variants of BRCA1/2 genes found in this
study are presented in Table 3. Overall, 24 pathogenic
variants in BRCA1 gene and 19 in BRCA2 gene were found
in 63 index cases mutations. Many of these mutations have
been reported in the BIC or previous studies in Korea. The
most frequent mutation was c.7480C[T in BRCA2 and it
was found in nine patients (14.3%). The next most frequent
mutations were c.1399A[T in BRCA2 gene and c.390C[A
in BRCA1 gene, which were found in four and three
patients, respectively. The large genomic rearrangements
found through MLPA were located in BRCA1 gene,
including an exon 1–14 deletion, exon 5–8 deletion, and
exon 22–24 deletion.
Table 2 Characteristics of the probands with BRCA1 large genomic rearrangements








TNBC Family history of BC
(number, closest degree)












B Yes (35) No No Yes Yes (1, second degree) Yes (1, 1st degree) Thyroid 57.2/39.2
C Yes (33) Yes Yes No Yes (1, first degree) No Lung 51.2/15.8
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Fig. 2 The 3 BRCA1 LGRs identified in the study using MLPA screening. The MLPA analysis demonstrates a exons 5–8 deletion, b exons
22–24 deletion, and c exons 1–14 deletion. Exons having a reduced peak ratio are denoted with the arrows
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Discussion
Here, we detected BRCA1/2 mutations in 13.2% of high-
risk breast cancer patients who were referred to a genetic
counseling center. Of the BRCA1/2 carriers, 5% (3 out of
63) were identified by MLPA after negative direct
sequencing results. All the large genomic rearrange-
ments were found in BRCA1 gene. Therefore, 10% of
BRCA1 carriers (3 out of 30) would have not been
identified if MLPA had not been conducted. In Korea,
BRCA1/2 mutation screening has been covered by
National Health Insurance since 2012 for those who meet
certain criteria. Because more than 95% of this study
population was recruited after 2012, our results could
provide a more current measure of the prevalence of
BRCA1/2 mutations.
The prevalence in familial breast cancer cases was
15.9% in this study, which was slightly lower than previous
results from Korea, which ranged 19.4–30.0% [19–22], and
results from Western countries [23]. Mutation prevalence
according to each personal factor in this study was com-
parable with previous Korean studies [19, 21, 22, 24, 25].
TNBC is an important factor used to select breast cancer
patients for BRCA1/2 mutation testing [5] and this was
confirmed in our study. Considering that the mutation
prevalence varies according to overlapped risk factors
Fig. 2 continued
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Table 3 Frequency of pathogenic variants of BRCA1 and BRCA2 genes in patients
Gene Exon/
intron
BIC nomenclature HGVS cDNA HGVS protein N
BRCA1 IVS5 IVS5?1G[A c.212?1G[A – 1
7 509C[A c.390C[A p.Tyr130* 3
11 1041_1042delAG c.922_923delAG p.Ser308Glufs* 1
11 c.922_924delAGCinsT p.Ser308* 1
11 1137delG c.1018delG p.Val340Glyfs* 1
11 1599C[T c.1480C[T p.Gln494* 1
11 c.14923_1494delTC p.Leu498Hisfs* 1
11 1630dupG c.1511dupG p.Lys505* 1
11 c.1516delA p.Arg506Glysfs* 2
11 c.2354T[A p.Leu785* 1
11 3415delC c.3296delC p.Pro1099Leufs* 1
11 3746dupA c.3627dupA p.Leu1210Glufs* 1
11 3819del5 c.3700_3704delGTAAA p.Val1210Aspfs* 1
c.4110C[T p.Glu1331* 1
16 5100G[T c.4981G[T p.Glu1661* 2
20 5379G[T c.5260G[T p.Glu1754* 2
IVS21 c.5332?4delA – 1
23 c.5445G[A p.Trp1815* 2
IVS23 IVS23?1G c.5467?1G[A – 1
24 5602delG c.5483delG p.Cys1828Leufs* 1
24 5615del11insA c.5496_5506delGGTGACCCGAGinsA p.Val1833Serfs* 1
1–14 Exon 1–14 deletion 1
5–8 Exon 5–8 deletion 1
22–24 Exon 22–24 deletion 1
BRCA2 7 173G[T c.518G[T p.Gly173Val 1
9 983del4 c.755_758delACAG p.Asp252Serfs* 2
10 1222delA c.994delA p.Ile332Phefs* 1
10 1627A[T c.1399A[T p.Lys467* 4
11 3026delCA c.2798_2799delCA p.Thr933Argfs* 1
11 c.3096_3110delAGATATTGAAGAAC p.Asp1033Ilefs* 1
11 3972del4 c.3744_3747delTGAC p.Ser1248Glufs* 3
11 6019C[T c.5791C[T p.Gln1931* 1
11 6781delG c.6553delG p.Ala2185Leufs* 1
14 c.7258G[T p.Glu2420* 2
15 7708C[T c.7480C[T p.Arg2494* 9
15 c.7486G[T p.Glu2420* 1
18 c.8300_8301insAC p.Pro2767Hisfs* 1
22 9179C[G c.8951C[G p.Ser2984* 1
23 9304C[T c.9076C[T p.Gln3026* 1
24 c.9253delA p.Thr3085Glnfs* 1
25 9503del2 c.9275_9276delAT p.Tyr3092Phefs* 1
25 9641T[G c.9413T[G p.Leu3138* 1
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(Appendix Table 4), multiple combinations of familial or
personal factors need to be considered for a more detailed
risk assessment.
The prevalence of large genomic rearrangement after
negative direct sequencing results in previous studies tar-
geting potential hereditary cancer subjects in diverse ethnic
groups ranged 0–5%, and was particularly low in Asian
countries [12, 26–33] (Appendix Table 5). With the
exception of two studies, most large genomic rearrange-
ments have been identified in the BRCA1 gene [12, 28], and
all of the large genomic rearrangements identified in Korea
[9, 10], including in this study, were in the BRCA1 gene.
The common characteristics of seven BRCA1 large geno-
mic rearrangement cases were that they all have a family
history of breast and/or ovarian cancer with at least one
additional personal factor. These personal factors included
bilateral breast cancer, young age at onset (B40 years old),
both breast and ovarian cancer, and TNBC. Therefore, at
least for BRCA1, the MLPA test should be considered for
breast cancer patients with a family history of breast and/or
ovarian cancer and additional personal factors such as
bilateral breast cancer, young age at onset, and TNBC
during the genetic counseling process. In our study popu-
lation with large genomic rearrangements, the compliance
with the prophylactic strategies was quite good (Appendix
Table 6).
Several limitations of this study should be mentioned.
Firstly, this study was performed by the patients of a single
institute. Secondly, we could not conduct MLPA test for all
BRCA1/2 small mutation non-carriers due to patient non-
participation, suggesting possible participation bias. How-
ever, this study was designed to reflect common clinical
settings, following the patients in the process of genetic
counseling. Thirdly, the detected large genomic rear-
rangements through MLPA test were not confirmed by
different MLPA probes or other platforms. However, the
three detected large genomic rearrangements were multi-
exon deletions and detected in multiple family members,
showing apparent inheritance patterns, suggesting mini-
mum probabilities of false positives. Fourth, the family
history was obtained by proband recollection and we did
not consider the validity and reliability of the information.
In conclusion, the prevalence of BRCA1/2 mutations
was dependent on familial and personal factors. Subjects
with both familial and personal factors had a much higher
risk of carrying BRCA1/2 mutations. The MLPA test for
BRCA1 mutation could be recommended for breast cancer
patients with a family member with breast and/or ovarian
cancer and additional personal factors, and who tested
negative for BRCA1/2 small mutations in initial testing.
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See Tables 4, 5, and 6.
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Table 4 The frequencies of BRCA1 and BRCA2 mutations according to combined family and personal characteristics
N of carriers/N of subjects (%)

































25/186 9/80 6/13 14/78 4/18 2/2 1/15 0/1 11/151
≥2




13.4 27.5 3/9 10/41 5/13 2/2 2/14 0/1 17/152
≥2nd
11.3 40.0 3/4 7/45 1/9 –/0 0/4 –/0 3/35
Family history of ovarian cancer
46.2 – 33.3 75.0 5/13 1/2 2/2 –/0 –/0 6/27
Early-onset breast cancer (≤40)
18.0 37.5 24.4 15.6 38.5 2/15 –/0 0/5 0/2 22/181
Bilateral breast cancer
22.2 50.0 38.5 11.1 50.0 13.3 –/0 1/3 0/2 7/44
Both breast and ovarian cancer
100.0 – 100.0 – 100.0 – – –/0 –/0 4/6
Multiple organ cancersa
6.7 33.3 14.3 0.0 – 0.0 33.3 – 0/2 2/25
Male breast cancer
0.0 – 0.0 – – 0.0 0.0 – 0.0
–/0
None
7.3 25.0 11.2 8.6 22.2 12.2 15.9 66.7 8.0
–
a Multiple organ cancer was defined as breast cancer patients with other primary organ cancer except ovarian cancer
Table 5 The prevalence of BRCA1/2 mutation and large genomic rearrangements in subjects without small mutation from direct sequencing
Country Number of subject Total prevalence (%) Prevalence among subjects with negative result of direct sequencing (%)
BRCA1 BRCA2 LRG in BRCA1 LRG in BRCA2
Hong Kong [24] 1236 4.6 5.1 0.4 0.3
Poland [27] 281 28.8 – 1.5 –
Lebanese Arab [22] 250 2.8 2.8 0.0 0.0
Mexico [29] 188 18.0 3.2 2.0 0.0
Slovakia [23] 585 14.5 11.5 5.0 0.0
Malaysia [11] 324 7.4 7.1 0.6a 0.3a
Malaysia [28] 100 – – 2.0a 0.0
Poland [26] 64 67 4.6 0.0
Singapore [25] 100 – – 2.0 1.0
Korea [8] 221 35.3 2.1 0.0
Korea [9] 122 – – 0.8 0.0
Korea—this study 478 6.3 6.9 1.0 0.0
a Not certain whether the prevalence is from whole subject or from limited subjects with BRCA1/2 mutation negative
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